| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Toxicology [S. A. B., T. R. D., M. W. A.] and National Toxicology Program [J. F. F., R. R. M.], National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709
The role of the type II cell in the development of pulmonary tumors induced in the adult A/J mouse (6 weeks of age) by treatment with a single dose (100 mg/kg, i.p.) of 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone (NNK) was investigated. Twenty-four h following treatment with NNK, the concentration of O6-methylguanine was similar in Clara and type II cells. However, hyperplasias were detected only along the alveolar septa in lungs 14 weeks after carcinogen treatment. Examination of the ultrastructure of several hyperplasias revealed that the proliferating cells resembled type II pneumocytes. The proliferating cells were cuboidal in shape, with centrally localized ovoid nuclei characterized by minor indentations. Lamellar bodies, one of the major hallmarks of the type II cell, were present in the cytoplasm. The progression of pulmonary lesions was followed by sacrificing mice at 4-week intervals from 14 to 54 weeks after treatment with NNK. From 34 to 42 weeks after treatment, progression to neoplasia was demonstrated by a decline in the frequency of hyperplasias and an increase in the frequency of adenomas. Approximately 50% of the adenomas were observed arising within hyperplasias. Carcinomas appeared to increase in frequency 34 weeks after carcinogen treatment and comprised greater than 50% of the pulmonary lesions by 54 weeks. Approximately 30% of the carcinomas were observed arising within adenomas. The growth pattern of carcinomas began to change from solid to mixed (solid and papillary) 42 weeks after NNK. Moreover, electron micrographie analysis demonstrated that, within a hyperplasia, proliferating type II cells could change from cuboidal to columnar in shape and could also exhibit nuclear indentations, both characteristics displayed by the Clara cell. Thus, this divergence of the type II cell from its well characterized morphological features indicates that the selective growth advantage which these initiated cells possess can result in changes to the normal ultrastructure of this cell as it progresses toward malignancy. DNA was isolated from 20 hyperplasias and screened for the presence of an activated K-ras gene. This gene was activated in 17 of 20 lesions, with 85% of the mutations involving a GC to AT transition within codon 12 (GGT to GAT), a mutation consistent with base mispairing produced by the formation of the O6-methylguanine adduct. This specificity for activation of the K-ras gene was identical to that observed previously in adenocarcinomas induced by NNK. These results indicate that the genesis of pulmonary neoplasia induced in the A/J mouse by NNK involves formation of the O6-methylguanine adduct within type II cells, which leads to the activation of the K-ras gene, followed by proliferation of type II cells and subsequent progression to a malignant tumor.
1 Present address: Molecular and Cellular Toxicology Group, Inhalation Toxicology Research Institute, PO Box 5890, Albuquerque, NM 87185.
2 To whom requests for reprints should be addressed.
This article has been cited by other articles:
![]() |
Y. Y. Kim, L. Von Weymarn, O. Larsson, D. Fan, J. M. Underwood, M. S. Peterson, S. S. Hecht, V. A. Polunovsky, and P. B. Bitterman Eukaryotic Initiation Factor 4E Binding Protein Family of Proteins: Sentinels at a Translational Control Checkpoint in Lung Tumor Defense Cancer Res., November 1, 2009; 69(21): 8455 - 8462. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D.F. Licchesi, W. H. Westra, C. M. Hooker, E. O. Machida, S. B. Baylin, and J. G. Herman Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung Carcinogenesis, May 1, 2008; 29(5): 895 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Tao, J. Fujimoto, T. Men, X. Ye, J. Deng, L. Lacroix, J. L. Clifford, L. Mao, C. S. Van Pelt, J. J. Lee, et al. Identification of the Retinoic Acid Inducible Gprc5a As a New Lung Tumor Suppressor Gene J Natl Cancer Inst, November 21, 2007; 99(22): 1668 - 1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice Cancer Res., August 15, 2007; 67(16): 7825 - 7832. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Wakamatsu, T. R. devereux, H.-H. L. Hong, and R. C. Sills Overview of the Molecular Carcinogenesis of Mouse Lung Tumor Models of Human Lung Cancer Toxicol Pathol, January 1, 2007; 35(1): 75 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Razani-Boroujerdi and M. L. Sopori Early Manifestations of NNK-Induced Lung Cancer: Role of Lung Immunity in Tumor Susceptibility Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 13 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Vuillemenot, J. A. Hutt, and S. A. Belinsky Gene Promoter Hypermethylation in Mouse Lung Tumors Mol. Cancer Res., April 1, 2006; 4(4): 267 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hutt, B. R. Vuillemenot, E. B. Barr, M. J. Grimes, F. F. Hahn, C. H. Hobbs, T. H. March, A. P. Gigliotti, S. K. Seilkop, G. L. Finch, et al. Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways Carcinogenesis, November 1, 2005; 26(11): 1999 - 2009. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Belinsky Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer Carcinogenesis, September 1, 2005; 26(9): 1481 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Bauer, A. M. Malkinson, and S. R. Kleeberger Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L685 - L703. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Pulling, B. R. Vuillemenot, J. A. Hutt, T. R. Devereux, and S. A. Belinsky Aberrant Promoter Hypermethylation of the Death-Associated Protein Kinase Gene Is Early and Frequent in Murine Lung Tumors Induced by Cigarette Smoke and Tobacco Carcinogens Cancer Res., June 1, 2004; 64(11): 3844 - 3848. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Vuillemenot, L. C. Pulling, W. A. Palmisano, J. A. Hutt, and S. A. Belinsky Carcinogen exposure differentially modulates RAR-{beta} promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis Carcinogenesis, April 1, 2004; 25(4): 623 - 629. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Takeuchi, K. Saoo, M. Yokohira, M. Ikeda, H. Maeta, M. Miyazaki, H. Yamazaki, T. Kamataki, and K. Imaida Pretreatment with 8-Methoxypsoralen, a Potent Human CYP2A6 Inhibitor, Strongly Inhibits Lung Tumorigenesis Induced by 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Female A/J Mice Cancer Res., November 15, 2003; 63(22): 7581 - 7583. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Belinsky, D. M. Klinge, C. A. Stidley, J.-P. Issa, J. G. Herman, T. H. March, and S. B. Baylin Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer Cancer Res., November 1, 2003; 63(21): 7089 - 7093. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tesfaigzi, P. S. Wright, and S. A. Belinsky SPRR1B overexpression enhances entry of cells into the G0 phase of the cell cycle Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L889 - L898. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Devereux, W. Holliday, C. Anna, N. Ress, J. Roycroft, and R. C. Sills Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years Carcinogenesis, October 1, 2002; 23(10): 1737 - 1743. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Wardlaw, N. Zhang, and S. A. Belinsky Transcriptional Regulation of Basal Cyclooxygenase-2 Expression in Murine Lung Tumor-Derived Cell Lines by CCAAT/Enhancer-Binding Protein and Activating Transcription Factor/cAMP Response Element-Binding Protein Mol. Pharmacol., August 1, 2002; 62(2): 326 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.C.H. John The effect of subcutaneous tumour implantation in a murine lung tumour model Eur. J. Cardiothorac. Surg., April 1, 2002; 21(4): 616 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. March, P. G. Marron-Terada, and S. A. Belinsky Refinement of an Orthotopic Lung Cancer Model in the Nude Rat Vet. Pathol., September 1, 2001; 38(5): 483 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Dahl, I. M. Grossi, D. P. Houchens, L. J. Scovell, M. E. Placke, A. R. Imondi, G. D. Stoner, L. M. De Luca, D. Wang, and J. L. Mulshine Inhaled Isotretinoin (13-cis Retinoic Acid) Is an Effective Lung Cancer Chemopreventive Agent in A/J Mice at Low doses: A Pilot Study Clin. Cancer Res., August 1, 2000; 6(8): 3015 - 3024. [Abstract] [Full Text] |
||||
![]() |
H.-H. L. Hong, T. R. Devereux, R. L. Melnick, C. R. Moomaw, G. A. Boorman, and R. C. Sills Mutations of ras Protooncogenes and p53 Tumor Suppressor Gene in Cardiac Hemangiosarcomas from B6C3F1 Mice Exposed to 1,3-Butadiene for 2 Years Toxicol Pathol, July 1, 2000; 28(4): 529 - 534. [Abstract] [PDF] |
||||
![]() |
S. A. Wardlaw, T. H. March, and S. A. Belinsky Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions Carcinogenesis, July 1, 2000; 21(7): 1371 - 1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B.J. Smith, A. Castonguay, P. J. Donnelly, K. R. Reid, D. Petsikas, and T. E. Massey Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells Carcinogenesis, September 1, 1999; 20(9): 1809 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liu, X. Qin, and S. L. Gerson Reduced lung tumorigenesis in human methylguanine DNA—methyltransferase transgenic mice achieved by expression of transgene within the target cell Carcinogenesis, February 1, 1999; 20(2): 279 - 284. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |